MARKET

ABBV

ABBV

AbbVie
NYSE

Real-time Quotes | Nasdaq Last Sale

118.87
+0.32
+0.27%
After Hours: 118.01 -0.86 -0.72% 19:55 07/29 EDT
OPEN
119.03
PREV CLOSE
118.55
HIGH
119.13
LOW
118.15
VOLUME
4.63M
TURNOVER
--
52 WEEK HIGH
119.13
52 WEEK LOW
79.11
MARKET CAP
209.95B
P/E (TTM)
41.98
1D
5D
1M
3M
1Y
5Y
TruWealth Advisors, LLC Buys Invesco Ultra Short Duration ETF, FIRST TR EXCHANGE, iShares ...
GuruFocus News · 11h ago
Suncoast Equity Management Buys Edwards Lifesciences Corp, Steris PLC, AbbVie Inc, Sells Check ...
GuruFocus News · 11h ago
AbbVie Inc. stock rises Thursday, still underperforms market
marketwatch.com · 11h ago
BRIEF-FDA Approves Expanded Botox® (Onabotulinumtoxina) Label To Include Eight New Muscles To Treat Adults With Upper Limb Spasticity
reuters.com · 14h ago
BigSur Wealth Management LLC Buys Airbnb Inc, SPDR Gold Shares ETF, AbbVie Inc, Sells ...
GuruFocus News · 15h ago
AbbVie Gets US FDA OK for Expanded Botox Label to Treat Adults with Upper Limb Spasticity
MT Newswires · 15h ago
Should You Buy AbbVie (ABBV) Ahead of Earnings?
Zacks.com · 16h ago
FDA Expands Allergan's BOTOX Label To Include Eight New Muscles In Patients With Upper Limb Spasticity
Benzinga · 16h ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ABBV. Analyze the recent business situations of AbbVie through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 26 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ABBV stock price target is 123.80 with a high estimate of 144.00 and a low estimate of 105.00.
EPS
Institutional Holdings
Institutions: 3.27K
Institutional Holdings: 1.27B
% Owned: 71.87%
Shares Outstanding: 1.77B
TypeInstitutionsShares
Increased
1.25K
52.13M
New
131
3.10M
Decreased
885
59.45M
Sold Out
98
4.59M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.26%
Pharmaceuticals & Medical Research
-0.31%
Key Executives
Chairman/Chief Executive Officer/Director
Richard Gonzalez
President/Vice Chairman - Management
Michael Severino
Vice Chairman - Management
Laura Schumacher
Chief Financial Officer/Executive Vice President
Robert Michael
Chief Human Resource Officer/Executive Vice President
Timothy Richmond
Executive Vice President
Henry Gosebruch
Executive Vice President
Azita Saleki - Gerhardt
Senior Vice President
Thomas Hudson
Senior Vice President
Elaine Sorg
Senior Vice President
Jeffrey Stewart
Senior Vice President
Carrie Strom
Vice President/Controller
Brian Durkin
Lead Director/Independent Director
Glenn Tilton
Independent Director
Robert Alpern
Independent Director
Roxanne Austin
Independent Director
William Burnside
Independent Director
Thomas Freyman
Independent Director
Brett Hart
Independent Director
Edward Liddy
Independent Director
Melody Meyer
Independent Director
Edward Rapp
Independent Director
Rebecca Roberts
Independent Director
Frederick Waddell
Declaration Date
Dividend Per Share
Ex-Div Date
06/17/2021
Dividend USD 1.3
07/14/2021
02/18/2021
Dividend USD 1.3
04/14/2021
10/30/2020
Dividend USD 1.3
01/14/2021
09/11/2020
Dividend USD 1.18
10/14/2020
06/17/2020
Dividend USD 1.18
07/14/2020
02/20/2020
Dividend USD 1.18
04/14/2020
11/01/2019
Dividend USD 1.18
01/14/2020
09/06/2019
Dividend USD 1.07
10/11/2019
06/20/2019
Dividend USD 1.07
07/12/2019
02/21/2019
Dividend USD 1.07
04/12/2019
11/02/2018
Dividend USD 1.07
01/14/2019
09/07/2018
Dividend USD 0.96
10/12/2018
06/14/2018
Dividend USD 0.96
07/12/2018
02/15/2018
Dividend USD 0.96
04/12/2018
10/26/2017
Dividend USD 0.71
01/11/2018
09/08/2017
Dividend USD 0.64
10/12/2017
06/23/2017
Dividend USD 0.64
07/12/2017
02/17/2017
Dividend USD 0.64
04/11/2017
10/31/2016
Dividend USD 0.64
01/11/2017
09/09/2016
Dividend USD 0.57
10/12/2016
About ABBV
AbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. AbbVie offers its products in various therapeutic categories, including Immunology products, which include Humira, Skyrizi and Rinvoq; Oncology products consists of Imbruvica and Venclexta; Aesthetics products include Botox Cosmetic, Juvederm Collection and other aesthetics; Neuroscience products, such as Botox Therapeutic, Vraylar, Duopa and Duodopa, and Ubrelvy; Eye care products consists of Lumigan, Alphagan and Restasis ; Women's health products incudes Lo Loestrin, Orilissa and other women's health; and Other key products, which includes Mavyret, Creon, Lupron, Linzess and Synthroid. The Company's products are sold worldwide directly to wholesalers, distributors, government agencies, health care facilities and independent retailers from AbbVie-owned distribution centers and public warehouses.

Webull offers kinds of AbbVie Inc stock information, including NYSE:ABBV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ABBV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ABBV stock methods without spending real money on the virtual paper trading platform.